uniQure (NASDAQ:QURE) Shares Down 4.9% After Analyst Downgrade

Shares of uniQure N.V. (NASDAQ:QURE) fell 4.9% during mid-day trading on Monday after Barclays lowered their price target on the stock from $31.00 to $25.00. Barclays currently has an equal weight rating on the stock. uniQure traded as low as $15.56 and last traded at $15.3020. 728,277 shares were traded during trading, a decline of 79% from the average session volume of 3,510,736 shares. The stock had previously closed at $16.09.

Other research analysts also recently issued reports about the company. Chardan Capital lifted their price target on uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a report on Monday, March 9th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. The Goldman Sachs Group decreased their price target on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Finally, Stifel Nicolaus set a $14.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 14,581 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the sale, the chief executive officer owned 660,658 shares in the company, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last 90 days. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of the stock. Private Trust Co. NA purchased a new stake in shares of uniQure during the third quarter worth about $28,000. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System lifted its position in shares of uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 627 shares in the last quarter. Finally, Ensign Peak Advisors Inc lifted its position in shares of uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 650 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The stock has a 50 day moving average price of $20.59 and a 200-day moving average price of $29.64. The stock has a market capitalization of $962.59 million, a price-to-earnings ratio of -4.45 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. On average, analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.